Description
Foundayo (orforglipron 0.8 mg) is a prescription oral weight-loss medication belonging to the class of GLP-1 receptor agonists. It was approved in April 2026 for chronic weight management in adults with obesity or overweight with related health conditions.
Foundayo 0.8 mg is the starting dose of a newer oral weight-loss drug (orforglipron). It’s designed to ease you into treatment before moving to higher, more effective doses.
🧾 Key details about the 0.8 mg tablet
- Strength: 0.8 mg (this is the starting dose)
- Form: Film-coated oral tablet
- How often: Once daily
- How to take:
- With or without food
- Swallow whole (don’t crush or chew)
👉 This dose is not the final dose—it’s used to let your body adjust before increasing gradually.
📈 Typical dosing schedule (important)
Treatment usually follows a step-up (titration) plan to reduce side effects:
- 0.8 mg daily (start)
- → after ≥30 days: 2.5 mg
- → after ≥30 days: 5.5 mg
- → then possibly 9 mg, 14.5 mg, or 17.2 mg depending on response
⚙️ How it works
Foundayo mimics a natural hormone (GLP-1) that:
- Reduces appetite
- Slows stomach emptying
- Helps you feel full sooner
This leads to reduced calorie intake and weight loss.
⚠️ Common side effects
Especially at the starting dose (0.8 mg), you may notice:
- Nausea
- Vomiting
- Diarrhea or constipation
- Stomach discomfort
These often improve as your body adapts.
👍 What makes it different
- ✅ Pill (not injection)
- ✅ Can be taken any time of day
- ✅ No food or water restrictions
That’s more flexible compared to older GLP-1 medications.
💡 Important notes
- Prescription only — must be taken under a doctor’s guidance
- Used alongside diet + exercise
- Dose increases depend on tolerance and results
- Not meant to be started or adjusted without medical advice
